

CYTOKINETICS INC
Form 8-K
March 22, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):

March 22, 2017

Cytokinetics, Incorporated

(Exact name of registrant as specified in its charter)

Delaware

000-50633

94-3291317

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

280 East Grand Avenue, South San Francisco,
California

94080

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code:

(650) 624 - 3000

Not Applicable

Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 8.01 Other Events.

Cytokinetics, Inc. announced that preclinical data for CK-2127107 were presented at the MDA Scientific Conference in Arlington, VA, showing that this next-generation fast skeletal troponin activator (FSTA) improves muscle function in mouse models of spinal muscular atrophy (SMA). In collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas"), Cytokinetics is developing CK-2127107 as a potential treatment for people living with SMA and certain other debilitating diseases and conditions associated with skeletal muscle weakness and/or fatigue.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

March 22, 2017

Cytokinetics, Incorporated

By: */s/ Sharon A. Barbari*

Name: Sharon A. Barbari

Title: Executive Vice President, Finance and Chief Financial Officer

Top of the Form

Exhibit Index

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release, dated March 22, 2017

46; account balances and the amounts reported in the statements of assets available for plan benefits.

(11) Subsequent Events

Effective January 1, 2011, the Employer reinstated the 401(k) match. The Employer now matches participant contributions annually up to 2% of total compensation for all employees.

Table of Contents

Schedule

DUKE 401(k) PLAN

Schedule H, Line 4i Schedule of Assets (Held at End of Year)

December 31, 2010

Party-in-interest	Identity	Description of investment	Current value
	Money market funds:		
*	Fidelity	Fidelity Retirement Money Market Portfolio	\$ 2,597,834
	Mutual funds:		
	Calamos	Calamos Growth Fund	4,358,225
*	Fidelity	Fidelity Balanced Fund	4,215,708
*	Fidelity	Fidelity Freedom 2005 Fund	84,278
*	Fidelity	Fidelity Freedom 2010 Fund	55,115
*	Fidelity	Fidelity Freedom 2015 Fund	946,797
*	Fidelity	Fidelity Freedom 2020 Fund	1,461,154
*	Fidelity	Fidelity Freedom 2025 Fund	990,044
*	Fidelity	Fidelity Freedom 2030 Fund	1,256,552
*	Fidelity	Fidelity Freedom 2035 Fund	1,123,943
*	Fidelity	Fidelity Freedom 2040 Fund	893,382
*	Fidelity	Fidelity Freedom 2045 Fund	454,477
*	Fidelity	Fidelity Freedom 2050 Fund	230,336
*	Fidelity	Fidelity Freedom Income Fund	463,319
*	Fidelity	Fidelity Inflation-Protected Bond Fund	2,467,601
*	Fidelity	Fidelity Spartan Total Market Index Fund	4,704,479
	Goldman Sachs	Goldman Sachs Mid-Cap Value CL A	5,317,328
	American	Growth Fund of America	7,203,342
	Janus	Janus Overseas I	7,016,829
	Pimco	Pimco Total Return Fund Admin Class	6,467,967
	Royce	Royce Low-Priced Stock Fund Inv Class	5,221,814
	TRP	TRP Mid-Cap Growth	338,857
	Van Kampen	Van Kampen Growth and Income Fund	5,139,877
			\$ 60,411,424
	Common and preferred stock:		
*	Duke Realty Corporation	Common and preferred stock	\$ 16,011,660
	Participant Directed Brokerage		
	Account		\$ 4,131,838
	Loans to participants:		
*	N/A	Participant loans at interest rates ranging from 4.25% to 9.25%	\$ 1,754,344
*	Denotes party-in-interest.		

See accompanying report of independent registered public accounting firm.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the trustees (or other persons who administer the employee benefit plan) have duly caused this annual report to be signed on its behalf by the undersigned hereunto duly authorized.

DUKE 401(k) PLAN

Date: June 29, 2011

/s/ Denise K. Dank
Denise K. Dank

Sr. Vice President of Human Resources

Chairman, Associate Benefits Committee